Panbela Therapeutics Total Liabilities 2020-2024 | PBLA

Panbela Therapeutics total liabilities from 2020 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Panbela Therapeutics Total Liabilities 2020-2024 | PBLA

Panbela Therapeutics total liabilities from 2020 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$142.2B
Bristol Myers Squibb (BMY)$117.1B
Gilead Sciences (GILD)$117.1B
Vertex Pharmaceuticals (VRTX)$105.1B
CSL (CSLLY)$85.9B
Regeneron Pharmaceuticals (REGN)$78.5B
GSK (GSK)$70.5B
Argenex SE (ARGX)$38B
Alnylam Pharmaceuticals (ALNY)$31.4B
BioNTech SE (BNTX)$27.4B
Biogen (BIIB)$21.7B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$17.7B
Moderna (MRNA)$15.5B
Genmab (GMAB)$13.5B
Incyte (INCY)$13.5B
BioMarin Pharmaceutical (BMRN)$12.7B
Insmed (INSM)$12.6B
Sarepta Therapeutics (SRPT)$11.6B
Bio-Techne Corp (TECH)$11.6B
Exact Sciences (EXAS)$10.8B
Vaxcyte (PCVX)$10.7B
QIAGEN (QGEN)$10.3B
Swedish Orphan Biovitrum (BIOVF)$9.8B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$9B
Roivant Sciences (ROIV)$8.7B
Ascendis Pharma (ASND)$8.4B
Repligen (RGEN)$8.2B